Adam Arceneaux, MD
Internal Medicine · Houma, LANPI 1538571252
Payments from drug & device makers
Across 222 payments — averaging $25.50 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$776
- Novo Nordisk$546
- Lilly USA, LLC$504
- AbbVie$486
- Boehringer Ingelheim$350
- Salix Pharmaceuticals, A Division Of Bausch Health US, LLC$244
- plus $3K from 28 others
What the payments were for
- Food & beverage$5,56898%
- Education$942%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AstraZeneca | 16 | $776 |
| Novo Nordisk | 23 | $546 |
| Lilly USA, LLC | 25 | $504 |
| AbbVie(2 entities) | 29 | $486 |
| Boehringer Ingelheim | 19 | $350 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 14 | $244 |
| Smith+Nephew | 3 | $228 |
| Esperion Therapeutics, Inc. | 2 | $219 |
| GSK | 13 | $212 |
| Organogenesis Inc. | 2 | $194 |
| Sanofi-aventis U.S. LLC | 7 | $183 |
| Amgen | 5 | $168 |
| Abbott | 3 | $151 |
| Merck | 10 | $136 |
| Convatec Inc. | 1 | $128 |
| Vanda Pharmaceuticals Inc. | 6 | $124 |
| Pfizer | 7 | $114 |
| Astellas Pharma US Inc | 2 | $111 |
| Hydrofera LLC | 1 | $111 |
| Takeda Pharmaceuticals U.S.A., Inc. | 6 | $95 |
| Bsn Medical Inc | 1 | $91 |
| Redhill Biopharma Inc. | 1 | $82 |
| Amarin Pharma, Inc. | 5 | $69 |
| Sanofi | 2 | $64 |
| E.r. Squibb & Sons, L.L.C. | 4 | $64 |
| Teva Pharmaceuticals USA, Inc. | 4 | $48 |
| Johnson & Johnson | 3 | $38 |
| Avanir Pharmaceuticals, Inc. | 2 | $30 |
| Boston Scientific | 1 | $20 |
| Reprise Biomedical, Inc. | 1 | $19 |
| Mylan Specialty L.p. | 1 | $15 |
| Vertiflex, Inc. | 1 | $14 |
| Genentech USA, Inc. | 1 | $13 |
| Optinose US, Inc. | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- CONVATEC INC.$128
- AQUACEL AG$128
- Grafix$125
- Iodosorb Ointment 40g USA$125
- RENASYS GO v2 HOME$125
- COLLAGENASE SANTYL$125
- Stravix$125
- FARXIGA$125
- Ozempic$125
- NEXLIZET$123
- NEXLETOL$123
- FreeStyle Libre$113
- HYDROFERA BLUE$111
- AIMOVIG$105
- RYBELSUS$104
- BREZTRI$100
How this compares
$5,662 in reported general payments places this provider in the 85th percentile of 1,528 internal medicine providers in Louisiana.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| MounjaroTirzepatide | 165 | $266,990 |
| FarxigaDapagliflozin Propanediol | 129 | $121,267 |
| JardianceEmpagliflozin | 79 | $111,124 |
| OzempicSemaglutide | 83 | $101,271 |
| VraylarCariprazine Hcl | 61 | $88,562 |
| Synjardy XrEmpagliflozin/Metformin Hcl | 77 | $80,556 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 92 | $64,206 |
| EliquisApixaban | 59 | $60,851 |
| Xigduo XrDapaglifloz Propaned/Metformin | 29 | $43,208 |
| RybelsusSemaglutide | 21 | $35,957 |
| JanuviaSitagliptin Phosphate | 28 | $35,804 |
| Stiolto RespimatTiotropium Br/Olodaterol Hcl | 59 | $34,967 |
| TrulicityDulaglutide | 29 | $34,833 |
| MyrbetriqMirabegron | 34 | $23,576 |
| LinzessLinaclotide | 20 | $19,364 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Lilly USA, LLCMounjaro, Trulicity | $504 | $301,823194 claims |
| Boehringer IngelheimJardiance, Synjardy Xr, Stiolto Respimat, Tradjenta | $350 | $243,956234 claims |
| AstraZenecaFarxiga, Breztri Aerosphere | $776 | $140,502159 claims |
| Novo NordiskOzempic, Rybelsus | $546 | $137,228104 claims |
| AbbVieVraylar, Linzess | $486 | $107,92681 claims |
| GSKTrelegy Ellipta, Anoro Ellipta | $212 | $71,762104 claims |
| PfizerEliquis | $114 | $60,85159 claims |
| MerckJanuvia | $136 | $35,80428 claims |
| Astellas Pharma US IncMyrbetriq | $111 | $23,57634 claims |
| Sanofi-aventis U.S. LLCSoliqua 100-33 | $183 | $17,40425 claims |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLCTrulance | $244 | $17,08912 claims |
| Johnson & JohnsonXarelto | $38 | $8,44012 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 1,528 internal medicine providers in Louisiana.
Other internal medicine in Houma
- William SmithNew Orleans$50.5M
- Robert JeanfreauMetairie$13.4M
- Katherine PearceBaton Rouge$12M
- Ernest ThompsonBaker$2.1M
- Brian LewisNew Orleans$2M
- Otis BarnumNatchitoches$1.8M
- Satinder SainiCrowley$1.8M
- Randall MillerEunice$1.2M
- Donna RyanBaton Rouge$991K
- Steven DeitelzweigNew Orleans$939K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.